Pharmacovigilance
Pharmacovigilance
| Product | Date | Safety information | Attachments |
|---|---|---|---|
| Fingolimod SPC (fingolimod) | 2021-01-13 | Updated recommendations to minimize the risk of drug-induced liver injury (DILI). |
|
| Gilenya (fingolimod) | 2021-01-10 | Updated recommendations to minimize the risk of drug-induced liver injury (DILI) |
|
| Fingolimod (Gilenya®) | 2016-03-21 | Risks related to the effects on the immune system . |
|
| Gilenya® - Fingolimod | 2014-03-02 | Hemophagocytic syndrome (HPS) reported in patients treated with Gilenya®. |
|
| Gilenya® - fingolimod | 2012-12-09 | Cardiovascular adverse events after the first dose of Gilenya® |
|